Literature DB >> 27492741

Effect of Repetitive Intracutaneous Injections with Local Anesthetics and Steroids for Acute Thoracic Herpes Zoster and Incidence of Postherpetic Neuralgia.

Ji-Zheng Cui1, Xiao-Bao Zhang2, Pin Zhu2, Zhi-Bin Zhao2, Zhu-Sheng Geng1, Yun-Hai Zhang1, Liang Tian2, Heng-Fei Luan2, Ji-Ying Feng2.   

Abstract

BACKGROUND: Treatment of established postherpetic neuralgia (PHN) is difficult and often disappointing. In this study, we assessed the efficacy of repetitive intracutaneous injections with local anesthetics and steroids in acute thoracic herpes zoster (HZ) pain, herpetic eruption, and incidence of PHN.
METHODS: Ninety-three patients with acute thoracic HZ were randomly assigned to receive a standard treatment of antiviral medication with p.o. analgesics or the standard treatment with the addition of repetitive intracutaneous injections of a local anesthetic and steroid mixture. Patients were permitted to take tramadol when the visual analog scale (VAS) ≥ 4. Pain assessment using VAS was conducted at the initial visit, as well as 1, 2, 4, 12, and 24 weeks after the end of the treatments.
RESULTS: In comparison with the standard treatment group, the VAS scores of the intracutaneous injection group were significantly lower during the study. The intracutaneous injection group also reported shorter duration of pain and skin eruption than the control group ( P  = 0.005 vs P  < 0.001, respectively). At 1 month post-therapy, 12.8% patients in the intracutaneous injection group reported zoster-associated pain, compared with 47.8% in the standard treatment group ( P  < 0.001). At 3 and 6 months post-therapy, the incidence of PHN was still significantly lower in the intracutaneous injection group than the standard treatment group. EuroQol VAS scores were significantly higher in the intracutaneous injection group vs standard treatment group (P < 0.001).
CONCLUSION: Repetitive intracutaneous injections with local anesthetics and steroids along with standard treatment significantly reduce the duration of pain and herpetic eruption and incidence of PHN.
© 2016 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  Herpes Zoster; Local Anesthetics; Postherpetic Neuralgia; Repetitive Intracutaneous Injection; Steroid; Thoracic

Mesh:

Substances:

Year:  2017        PMID: 27492741     DOI: 10.1093/pm/pnw190

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  5 in total

1.  Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis.

Authors:  Junhyeok Kim; Min Kyoung Kim; Geun Joo Choi; Hwa Yong Shin; Beom Gyu Kim; Hyun Kang
Journal:  Korean J Pain       Date:  2021-10-01

2.  The effectiveness of repetitive paravertebral block with ropivacaine and dexmedetomidine for the prevention of postherpetic neuralgia in patients with acute herpes zoster.

Authors:  Fan Yang; Pingsheng Liao; Yujuan You; Yingping Liang; Yanhui Hu
Journal:  Postepy Dermatol Alergol       Date:  2021-10-25       Impact factor: 1.837

Review 3.  Efficacy of local anaesthetic and steroid combination in prevention of post-herpetic neuralgia: A meta-analysis.

Authors:  Xiaolu Zhang; Zhiwei Wang; Yiyuan Xian
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 1.088

4.  Effect of CT-Guided Gasserian Ganglion Block with Local Anesthetics and Steroids on Acute/Subacute Zoster-Related Trigeminal Neuralgia: A Multicenter Retrospective Study.

Authors:  Zhe Sun; Lu Liu; Hongbing Liu; Fang Luo
Journal:  J Pain Res       Date:  2022-08-10       Impact factor: 2.832

5.  Single intracutaneous injection of local anesthetics and steroids alleviates acute nonspecific neck pain: A CONSORT-perspective, randomized, controlled clinical trial.

Authors:  Xiao-Na Yang; Zhu-Sheng Geng; Xiu-Li Zhang; Yun-Hai Zhang; Xin-Ling Wang; Xiao-Bao Zhang; Ji-Zheng Cui
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.